Furthermore, the role of FcγR polymorphisms in GPA is supported by studies showing that patients homozygous for the FcγRIIA131H or FcγRIIIA158V alleles respond faster to immunosuppressive treatment with Rituximab and their disease progresses significantly faster than in other patients (120, 121). The gene discussed is FCGR2A; the disease is granulomatosis with polyangiitis.